Company / Capital Expenditures
Kymera Therapeutics, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.4M
FY2025
5-year range
$532.0K / $34.5M
FY2021-FY2025
Trend
-88.7%
vs FY2024
Sector context
#105 of 194
Health Care
What the data says
At $1M, Kymera Therapeutics, Inc.'s capital expenditures ranks #105 of 194 in the Health Care sector. Declined from $34M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +22.2%.
Declined from $34M to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -20.1%
- 5-Year CAGR
- +22.2%
- 10-Year CAGR
- -
Sector benchmark
#105 of 194 in Health CareTop 54% of 194This company $1.4M Sector average $117.5M
▼
-98.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.2%, indicating consistent growth.
- In FY2025, capital expenditures decreased 88.7% year-over-year.
- Ranks #105 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -88.7% |
| FY2024 | $12.8M | -62.8% |
| FY2023 | $34.5M | +1115.8% |
| FY2022 | $2.8M | +433.1% |
| FY2021 | $532.0K | +0.0% |
| FY2020 | $532.0K | +0.0% |
| FY2019 | $532.0K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026